CMV glycoproteins and recombinant vectors
US10760097B2 · kind B2 · utility
4Cited by
15References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 30, 2017 |
| Grant date | Sep 1, 2020 |
| Priority date | — |
| Expiry date | Nov 30, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US11 glycoprotein or a homolog thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.